Maze Therapeutics (NASDAQ:MAZE) Price Target Cut to $51.00 by Analysts at JPMorgan Chase & Co.

Maze Therapeutics (NASDAQ:MAZE) had its target price cut by JPMorgan Chase & Co. from $53.00 to $51.00 in a research note released on Wednesday,Benzinga reports. They currently have an overweight rating on the stock.

Other equities analysts have also issued reports about the stock. HC Wainwright reiterated a “buy” rating and issued a $110.00 price objective on shares of Maze Therapeutics in a research report on Thursday, September 24th. Wall Street Zen downgraded shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Citigroup assumed coverage on shares of Maze Therapeutics in a research note on Wednesday, September 23rd. They issued a “buy” rating and a $50.00 target price for the company. Canaccord Genuity Group started coverage on shares of Maze Therapeutics in a report on Monday, October 19th. They issued a “buy” rating and a $75.00 target price on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Monday, September 21st. Three research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $63.91.

Maze Therapeutics Stock Up 3.6%

Maze Therapeutics stock opened at $36.73 on Wednesday. The stock has a 50 day moving average of $28.32 and a two-hundred day moving average of $31.63. Maze Therapeutics has a twelve month low of $21.95 and a twelve month high of $53.65. The stock has a market capitalization of $2.04 billion, a price-to-earnings ratio of -13.86 and a beta of 2.04. The company has a current ratio of 14.14, a quick ratio of 18.31 and a debt-to-equity ratio of 0.09.

Maze Therapeutics (NASDAQ:MAZE) last released its earnings results on Monday, November 9th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.01). As a group, research analysts expect that Maze Therapeutics will post -2.70 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Jason V. Coloma sold 34,501 shares of the company’s stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $26.29, for a total transaction of $907,031.29. Following the transaction, the chief executive officer directly owned 18,151 shares of the company’s stock, valued at $477,189.79. This represents a 65.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Atul Dandekar sold 7,500 shares of the stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $27.58, for a total transaction of $206,850.00. Following the completion of the transaction, the insider owned 26,250 shares of the company’s stock, valued at $723,975. This represents a 22.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 176,849 shares of company stock valued at $4,741,878 over the last quarter. Company insiders own 5.30% of the company’s stock.

Institutional Trading of Maze Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. TRV GP IV LLC acquired a new position in Maze Therapeutics during the second quarter worth about $133,502,907. ARCH Venture Management LLC acquired a new stake in shares of Maze Therapeutics during the 2nd quarter valued at approximately $122,983,582. BlackRock Inc. purchased a new stake in shares of Maze Therapeutics during the 2nd quarter worth approximately $104,525,000. Jupiter Topco LLC purchased a new stake in shares of Maze Therapeutics during the 2nd quarter worth approximately $101,764,000. Finally, Alphabet Inc. purchased a new stake in shares of Maze Therapeutics during the 2nd quarter worth approximately $41,435,000.

About Maze Therapeutics

Maze Therapeutics is a clinical-stage biotechnology company developing precision medicines for people with serious diseases. Its research uses human genetics and functional genomics to identify disease-related biological pathways and potential drug targets. The company’s Maze Compass platform is designed to connect genetic insights with biological research to guide drug discovery and development. Its investigational programs have included approaches for APOL1-mediated kidney disease and Pompe disease; these are not marketed treatments.